ep expect previou guid rang
due strong revenu growth margin particularli
diagnost life scienc updat model
accordingli also want think mean sinc
time unusu
time chosen make announc five
week set origin guidanc rang well
end quarter one interpret first two month
quarter except strong simpli
need make disclosur meet investor
howev
investor ask whether addit
motiv could get possibl inform price
stock negoti larg deal would involv equiti
compon argument merit particularli sinc wsj
recent report competitor dental unit sale danah
comment remark quiet
deal well year despit continu strateg
deal repeat would feel certain type deal
would bullish chose foray
pharma-focus life scienc tool particularli area augment
exist vertic allow cross-sel gener
less bullish diagnost dental opportun though
interest asset exist could make strong case
certain synergi area would bullish danah
could find good busi undermanag good
multipl seem rare right gener dont
want establish entir new platform think
compani could benefit
cross sell exist
custom particularli life scienc tool area
read think announc read posit
primarili inclin make
posit read-through life scienc strength sinc
diagnost strength appar lot cepheid
doesnt overlap much tool player
benefit sever flu season
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
compani prioriti stock list
exclud amort acquir intang asset
one-tim restructur impair charg
compani data secur llc estim reuter
summari fy end gross sell gener research oper interest expens incom pre-tax incom tax expens net incom continu non- dilut share margin analysisgross analysi y/i total share growth ebit ebitda growth ebit ebitda growth ebit ebitda appli growth ebit ebitda total growth growth growth revenu data total net cash debt ttm debt ttm flow capit free cash free cash flow per invest normal per sourc compani data secur llc estimatesin million except per sharenon- incom statementrevenu analysi corpor
price target nc
price target dcf-base wacc termin noplat growth repres
ep estim upsid price target rate would like come rapid improv
dental segment continu cyclic improv environmental/appli stronger-than-expect
progress deal integr new deal particularli strong synergi outlook could also drive
potenti upsid downsid risk could caus deterior end market condit over-reach
larg deal integr risk
result impress strong two element strategi
caus us favor other tool space first think compani put disproportion focu
clinic diagnost market view favor pharma-focus strategi
certain peer second think compani continu view primarili industri
conglomer rather focus life scienc tool compani may lend well
type innov necessari drive higher growth danah busi system db
undergird entir cultur consist yield margin expans think may
much differenti investor believ particularli come top line
washington dc-base corp nyse industri conglomer focus use
continu improv techniqu improv perform acquir busi compani
product typic distinguish strong brand name innov technolog major market
posit razor/razor-blad busi model compani oper four segment life scienc
diagnost dental environment appli life scienc segment sell mass spec
chromatographi filtrat microscopi centrifug flow cytometri product pharma academia
certain industri end market diagnost sell wide varieti diagnost test equip
hospit lab refer lab patholog lab point-of-car set dental sell orthodont
implant dispos tool larger equip dental offic environment appli divid
two piec water qualiti product identif
